Titlebook: Urologic Oncology; Multidisciplinary Ca Kelly L. Stratton,Alicia K. Morgans Book 2022 The Editor(s) (if applicable) and The Author(s), unde

Vulnerable

Radiotherapy for Advanced Prostate Cancer,ic grading systems [1]. Prostate cancer is no exception, and accurate risk stratification is paramount to appropriately guide therapy for men with prostate cancer. Traditionally, the treatment of localized or non-metastatic malignancies includes radical local therapy with either radiotherapy or surg

Irritate

Optimizing Perioperative Treatment for Kidney Cancer,icians can risk-stratify surgical candidates, make recommendations on targeting vulnerabilities and deficits identified in preoperative assessment, and summarize best practices regarding surgical considerations, postoperative care, and follow-up. In this chapter, we review traditional and commonly u

Antarctic

Surgical Treatment for Metastatic Kidney Cancer,atic renal cell carcinoma. The role of cytoreductive nephrectomy and metastasectomy for patients with metastatic disease has evolved accordingly. Historically, level 1 evidence supported the use of cytoreductive nephrectomy in patients treated with interferon. While retrospective studies suggest cyt

聯(lián)合

因無茶而冷淡

極小量

Immunotherapy,eckpoint inhibitors (ICIs) have been approved by the US FDA, adding more options for RCC therapies. Recent clinical trials have shown the potency of ICIs, including anti-PD-1 and anti-CTLA-4 antibodies, as combination and monotherapy in both metastatic and local RCC. However, there is a continued ne

lacrimal-gland

Evolving Treatment in Non-muscle-Invasive Bladder Cancer,g many other aspects. Historically, NMIBC has been treated with surgical resection and intravesical BCG. More recently, many other forms of intravesical therapy including non-BCG immunotherapy, chemotherapy, gene therapy, viral therapy, and others, have been studied to treat patients with NMIBC. Pri

Tdd526

Neoadjuvant and Adjuvant Therapy for Muscle-Invasive Bladder Cancer,sed chemotherapy prior to surgical resection to address occult disseminated disease reduces risk of recurrence and is the current standard of care for MIBC, supported by level I evidence. While adjuvant chemotherapy could theoretically offer similar benefit, postoperative cisplatin-based chemotherap

Monocle

Bladder-Sparing Approaches to Treatment of Muscle-Invasive Bladder Cancer,ble for consideration based on certain selection criteria. This chapter describes the clinical entity of MIBC, discusses the selection criteria utilized for evaluating candidacy for SBP, and addresses a multitude of bladder-sparing approaches that have been utilized both historically and in current

種類

Treatment of Metastatic Bladder Cancer,ular biology and the tumor microenvironment of bladder cancer has unlocked new opportunities for treatment. Immune checkpoint blockade with programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) antibodies has demonstrated durable responses in a subset of patients in the first- and